Teva Pharmaceutical Industries (SWX:TEVA) - Hisse Senedi Fiyatı, Haberler ve Analizler

TEVA Stoklara Genel Bakış

TEVA temel anali̇z
Kar Tanesi Skoru
Değerleme	5/6
Gelecekteki Büyüme	4/6
Geçmiş Performans	0/6
Finansal Sağlık	2/6
Temettüler	0/6

Ödüller

Adil değer tahminimizden 78.2% daha düşük bir oranda işlem görüyor

Kazançların yılda 65.77% oranında artması öngörülüyor

Kazançlar son 5 yılda yılda 17.9% oranında arttı

Rakiplerine ve sektöre kıyasla iyi değerde işlem görüyor

Risk Analizi

Hisse senetleri oldukça likit değildir

Teva Pharmaceutical Industries Limited Rakipler

Sandoz Group

SWX:SDZ

CHF 17.4b

Galderma Group

SWX:GALD

CHF 20.2b

Dottikon ES Holding

SWX:DESN

CHF 3.2b

Novartis

SWX:NOVN

CHF 183.1b

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Teva Pharmaceutical Industries
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$7.85
52 Haftanın En Yüksek Seviyesi	US$0
52 Haftanın En Düşük Seviyesi	US$0
Beta	0.87
11 Aylık Değişim	0%
3 Aylık Değişim	0%
1 Yıllık Değişim	0%
33 Yıllık Değişim	0%
5 Yıllık Değişim	0%
Halka arzdan bu yana değişim	-85.75%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	TEVA	CH Pharmaceuticals	CH Pazar
7D	0%	-2.5%	-1.7%
1Y	0%	7.2%	5.0%

Getiri vs. Endüstri: TEVA geçen yıl % 7.2 oranında getiri sağlayan Swiss Pharmaceuticals sektörünün gerisinde kaldı.

Getiri vs Piyasa: TEVA geçen yıl % 5 oranında getiri sağlayan Swiss Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is TEVA's price volatile compared to industry and market?
TEVA volatility
TEVA Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	2.9%
Market Average Movement	3.4%
10% most volatile stocks in CH Market	6.5%
10% least volatile stocks in CH Market	1.6%

İstikrarlı Hisse Senedi Fiyatı: TEVA hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: TEVA 'un son bir yıldaki oynaklık değişimini belirlemek için Yetersiz veri.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
1901	37,000	Richard Francis	www.tevapharm.com

Teva Pharmaceutical Industries Limited, Kuzey Amerika, Avrupa, İsrail ve uluslararası alanda jenerik ilaçlar, özel ilaçlar ve biyofarmasötik ürünler geliştirmekte, üretmekte, pazarlamakta ve dağıtmaktadır. Tabletler, kapsüller, enjektabllar, inhalantlar, sıvılar, transdermal bantlar, merhemler ve kremler gibi çeşitli dozaj formlarında jenerik ilaçlar; parenteral ve katı dozaj formlarında steril ürünler, hormonlar, yüksek potensli ilaçlar ve sitotoksik maddeler; ve tıbbi cihazlar ve kombinasyon ürünleri ile jenerik ürünler sunmaktadır. Şirket, merkezi sinir sistemi (MSS), solunum ve onkoloji alanlarına odaklanmaktadır.

Teva Pharmaceutical Industries Limited Temel Bilgiler Özeti

Teva Pharmaceutical Industries'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
TEVA temel i̇stati̇sti̇kler
Piyasa değeri	CHF 16.54b
Kazançlar(TTM)	-CHF 851.86m
Gelir(TTM)	CHF 14.90b

1.1x

P/S Oranı

-19.4x

F/K Oranı

TEVA aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
TEVA gelir tablosu (TTM)
Gelir	US$16.77b
Gelir Maliyeti	US$8.41b
Brüt Kâr	US$8.36b
Diğer Giderler	US$9.32b
Kazançlar	-US$959.00m

Son Raporlanan Kazançlar

Sep 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-0.85
Brüt Marj	49.84%
Net Kâr Marjı	-5.72%
Borç/Özkaynak Oranı	297.3%

TEVA uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

TEVA Stoklara Genel Bakış

Ödüller

Risk Analizi

Teva Pharmaceutical Industries Limited Rakipler

SWX:SDZ

CHF 17.4b

SWX:GALD

CHF 20.2b

SWX:DESN

CHF 3.2b

SWX:NOVN

CHF 183.1b

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Teva Pharmaceuticals Limited Unveils New Phase 3 Positive Results for Olanzapine Lai, and Presents Real-World Data on Uzedy At Psych Congress 2024

Alvotech and Teva Pharmaceutical Industries Ltd. Announce U.S. FDA Approval of Additional Presentation of SELARSDI (ustekinumab-aekn)

Teva Pharmaceutical Industries Limited to Report Q3, 2024 Results on Nov 06, 2024

Second quarter 2024 earnings released: US$0.75 loss per share (vs US$0.78 loss in 2Q 2023)

Teva Pharmaceuticals and Sanofi Announce Accelerated Timeline for Anti-TL1A Phase 2b Program in Patients with Inflammatory Bowel Disease

Teva Pharmaceutical Industries Limited Announces First Phase 3 Evidence of Efficacy and Safety of an Anti-CGRP Monoclonal Antibody in Children in AJOVY (fremanezumab) Space Trial for Prevention of Episodic Migraine

Recent updates

Teva Pharmaceuticals Limited Unveils New Phase 3 Positive Results for Olanzapine Lai, and Presents Real-World Data on Uzedy At Psych Congress 2024

Alvotech and Teva Pharmaceutical Industries Ltd. Announce U.S. FDA Approval of Additional Presentation of SELARSDI (ustekinumab-aekn)

Teva Pharmaceutical Industries Limited to Report Q3, 2024 Results on Nov 06, 2024

Second quarter 2024 earnings released: US$0.75 loss per share (vs US$0.78 loss in 2Q 2023)

Teva Pharmaceuticals and Sanofi Announce Accelerated Timeline for Anti-TL1A Phase 2b Program in Patients with Inflammatory Bowel Disease

Teva Pharmaceutical Industries Limited Announces First Phase 3 Evidence of Efficacy and Safety of an Anti-CGRP Monoclonal Antibody in Children in AJOVY (fremanezumab) Space Trial for Prevention of Episodic Migraine

Teva Pharmaceutical Industries Limited to Report Q2, 2024 Results on Jul 31, 2024

Teva Pharmaceutical Industries Ltd Announces New AJOVY® (Fremanezumab) Migraine Prevention Data Challenges Treatment Pauses

Teva Pharmaceutical Industries Limited Announces Launch of Authorized Generic of Victoza® (Liraglutide Injection 1.8Mg), in the United States

Teva Pharmaceutical Industries Limited Announces AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets Now U.S. FDA Approved as a One Pill, Once-Daily Treatment Option for Clinically Therapeutic Doses (24–48 mg/day)

Teva Pharmaceutical Industries Limited Announces Management Changes, Effective June 3, 2024

Teva Pharmaceutical Industries Limited Reaffirms Earnings Guidance for the Full Year 2024

First quarter 2024 earnings released: US$0.12 loss per share (vs US$0.18 loss in 1Q 2023)

Teva Pharmaceutical Industries Limited, Annual General Meeting, Jun 06, 2024

Teva Confirms Efficacy and Safety of AJOVY for the Prevention of Migraine with Results from Phase 3 Trial in China

Teva Pharmaceutical Industries Limited to Report Q1, 2024 Results on May 08, 2024

Full year 2023 earnings released: US$0.50 loss per share (vs US$2.12 loss in FY 2022)

Teva Pharmaceutical Industries Limited Reports Impairment Charges for the Fourth Quarter Ended December 31, 2023

Teva Pharmaceutical Industries Limited Announces Earnings Guidance for Full Year 2024

Court for the District of New Jersey Issues A Decision That Teva Pharmaceuticals Does Not Infringe Any Asserted Claims of Corcept Therapeutics Incorporated’s U.S. Patents

Teva Pharmaceutical Industries Limited Announces Post Hoc Phase 3 Data Analysis Shows AJOVY (Fremanezumab) Reduced Migraine Attacks in Adults with Migraine and Co-Morbid Obesity

Third quarter 2023 earnings released: EPS: US$0.071 (vs US$0.05 in 3Q 2022)

Teva Pharmaceutical Industries Ltd. Appoints R. Ananthanarayanan (Ananth) as CEO of Its Teva Active Pharmaceutical Ingredients Business

Teva Pharmaceutical Industries Limited Announces Phase IV Unite Study Shows Ajovy® (Fremanezumab) Reduced Migraine Attacks and Depression Symptoms in Migraine Sufferers with Major Depressive Disorder

Teva Pharmaceutical Industries Limited to Report Q3, 2023 Results on Nov 08, 2023

Teva Announces Changes to Executive Management Team

Teva Pharmaceutical Industries Limited Appoints Varda Shalev as Member of the Board, Effective September 1, 2023

Second quarter 2023 earnings released: US$0.77 loss per share (vs US$0.21 loss in 2Q 2022)

Teva Pharmaceutical Industries Limited Reports Impairment Charges for the Second Quarter Ended June 30, 2023

Teva Announces Appointment of Dr. Angus Grant to Executive Vice President, Business Development, Effective August 1, 2023

Teva Pharmaceutical Industries Limited to Report Q2, 2023 Results on Aug 02, 2023

Teva Pharmaceutical Industries Ltd. Announces Further Positive Data from the Pan-European Research Study

Teva to Present Data at the 2023 American Headache Society Annual Scientific Meeting Demonstrating AJOVY

Teva Pharmaceuticals Presents Real-World Data for Austedo (Deutetrabenazine) Tablets with 4-Week Patient Titration Kit At Psych Congress Elevate 2023

Teva to Present Data Demonstrating UZEDY™ (risperidone) Extended-Release Injectable Suspension Significantly Prolonged Time to Impending Relapse for Adults with Schizophrenia at the American Psychiatric Association’s 2023 Annual Meeting

Teva Pharmaceutical Industries Limited Announces That Once-Daily Austedoxr (Deutetrabenazine) Extended-Release Tablets Are Now Available for Adults in the United States

First quarter 2023 earnings released: US$0.19 loss per share (vs US$0.86 loss in 1Q 2022)

Teva Pharmaceutical Industries Limited Reaffirms Earnings Guidance for the Full Year 2023

Full year 2022 earnings released: US$2.12 loss per share (vs US$0.38 profit in FY 2021)

Teva Pharmaceutical Industries Limited Provides Earnings Guidance for the Year 2023

Teva Pharmaceutical Industries Limited to Report Q4, 2022 Results on Feb 08, 2023

Karo Pharma AB (publ) agreed to acquire of Six brands of Teva for DKK 84 million.

Teva Pharmaceutical Industries Limited Appoints Richard Francis as President, Effective January 1, 2023

Third quarter 2022 earnings released: EPS: US$0.05 (vs US$0.27 in 3Q 2021)

Teva Pharmaceutical Industries Limited Revises Earnings Guidance for the Year 2022

Teva Pharmaceutical Industries Limited Reaches Agreement with Arkansas to Settle the State’s Price Fixing Claims

Teva Pharmaceutical Industries Limited to Report Q3, 2022 Results on Nov 03, 2022

Teva Pharmaceutical Industries Limited Presents Studies of Effectiveness of AJOVY for Treatment of Migraine in Patients with Co-morbid Depression

Exelixis, Inc. Files Complaint in the United States District Court for the District of Delaware for Patent Infringement against Teva Pharmaceutical Industries Limited, Teva Pharmaceuticals Development, Inc. and Teva Pharmaceuticals USA, Inc

Teva Pharmaceutical Industries Limited Announces European Commission Grants Marketing Authorization for Ranivisio (Ranibizumab), for Age-Related Macular Degeneration (AMD) the Most Common Cause of Blindness in Developed Countries

Teva Pharmaceutical Industries Limited Provides Earnings Guidance for the Year 2022

Teva Pharmaceutical Industries Limited Announces Impairment Charges for the Second Quarter Ended June 30, 2022

Second quarter 2022 earnings released: US$0.21 loss per share (vs US$0.19 profit in 2Q 2021)

Teva Pharmaceutical Industries Limited Appoints Eric A. Hughes as Executive Vice President, Global R&D and Chief Medical Officer

Teva Pharmaceutical Industries Limited to Report Q2, 2022 Results on Jul 27, 2022

Teva Pharmaceutical Industries Limited Welcomes the UK Medicines & Healthcare Regulatory Agency Decision to Grant A Licence for Ongavia

Teva Pharmaceutical Industries Limited Revises Earnings Guidance for the Full Year 2022

First quarter 2022 earnings released: US$0.86 loss per share (vs US$0.07 profit in 1Q 2021)

Teva Pharmaceutical Industries Limited to Report Q1, 2022 Results on May 03, 2022